Merrimack is committed to the fight against cancer. We are a science-driven community seeking to understand the complexity of the disease, engineer better solutions and deliver life-saving results for patients.
A recent manuscript shows that adaptive ErbB3 signaling is a key factor limiting the utility of anti-IGF-1R agents. MM-141, a bispecific tetravalent antibody, co-blocks IGF and heregulin-induced signaling and induces degradation of receptor complexes containing IGF-1R and ErbB3. MM-141 also potentiates mTOR inhibitors and taxanes, supporting its ongoing clinical development.
Merrimack is delighted to announce its alliance with the Pancreatic Cancer Action Network, an organization dedicated to advancing research, supporting patients and creating hope for those affected by pancreatic cancer.
MM-398, an exploratory new medicine for pancreatic cancer, is founded on a technology that allows us to increase a tumor cell's exposure to chemotherapy. Learn more about MM-398.
Professor Peter Sorger of Harvard Medical School discusses the science of systems biology and its potential impact on cancer care.
MM-121 is a novel signaling inhibitor being developed by Merrimack and Sanofi Oncology across multiple cancer indications, including breast, lung and ovarian cancer. Our research suggests that MM-121’s target, HER3, could play a substantial role in the growth and survival of cancer. Learn more about MM-121 and its clinical program here.